Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies

• Published in: Therapeutic drug monitoring Vol. 20; no. 2; p. 202
• Main Authors: Azzazy, H M, Chou, P P, Tsushima, J H, Troxil, S, Gordon, M, Avers, R J, Chiappetta, E, Duh, S H, Christenson, R H
• Format: Journal Article
• Language: English
• Published: United States 01.04.1998
• Subjects: Anti-Bacterial Agents - blood; Anti-Bacterial Agents - chemistry; Calibration; Chromatography, High Pressure Liquid - standards; Drug Contamination - prevention & control; Drug Monitoring - methods; Drug Monitoring - standards; Enzyme Multiplied Immunoassay Technique - standards; Fluorescence Polarization Immunoassay - methods; Fluorescence Polarization Immunoassay - standards; Humans; In Vitro Techniques; Infection - blood; Infection - drug therapy; Infection - etiology; Kidney Diseases - blood; Kidney Diseases - complications; Kidney Transplantation - physiology; Linear Models; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Vancomycin - blood; Vancomycin - chemistry
• ISSN: 0163-4356
• DOI: 10.1097/00007691-199804000-00011

The authors evaluated the performance characteristics of the Abbott AxSYM Vancomycin II immunoassay in sera of patients with (n = 93 samples) and without (n = 327 patients) renal dysfunction. Correlation of vancomycin measurements with the Abbott AxSYM Vancomycin, Abbott TDx/TDxFLx, Syva enzyme-multiplied immunoassay technique (EMIT), DuPont automated chemistry analyzer (ACA), and high-performance liquid chromatography methods showed acceptable correlation as indicated by: slope values >0.95, r-values >0.97, y-intercepts <1.7 microg/ml, and S(y/x) ranging from 9% to 15% of the average vancomycin value. The AxSYM Vancomycin II assay showed acceptable correlation with AxSYM vancomycin, TDx/TDxFLx, and high-performance liquid chromatography methods in 93 samples from patients with renal dysfunction. This monoclonal antibody-based assay showed no apparent interference from the presence of human antimouse antibody (HAMA) or the microbiologically inactive vancomycin crystalline degradation product (CDP). The authors conclude that the AxSYM Vancomycin II assay showed satisfactory agreement with other methods tested in this study.